Dataset for: Bioprinted platform for parallelized screening of engineered microtissues in vivo

Published in:

Cell Stem Cell, https://doi.org/10.1016/j.stem.2025.03.002

Bioprinted Platform for Parallelized Screening of Engineered Microtissues In Vivo

Colleen E. O’Connor*,1,2, Fan Zhang*,1,2, Anna Neufeld3, Olivia Prado1,2, Susana P. Simmonds1,2, Chelsea L. Fortin1,2,4, Fredrik Johansson1,2, Jonathan Mene1,2, Sarah H. Saxton1,2, Irina Kopyeva1, Nicole E. Gregorio1, Zachary James1, Cole A. DeForest1,2,5, Elizabeth C. Wayne1,2, Daniela M. Witten3,6, Kelly R. Stevens1,2,4,7,8,#

1Department of Bioengineering, University of Washington, Seattle, WA 98195, USA

2Institute for Stem Cell and Regenerative Medicine, Seattle, WA 98195, USA

3Department of Statistics, University of Washington, Seattle, WA, USA

4Department of Laboratory Medicine & Pathology, University of Washington, Seattle, WA 98195, USA

5Department of Chemical Engineering, University of Washington, Seattle, WA 98195, USA

6Department of Biostatistics, University of Washington, Seattle, WA, USA

7Center for Cardiovascular Biology, University of Washington, Seattle, WA 98195, USA

8Brotman Baty Institute, Seattle, WA 98195, USA

*Authors contributed equally

#Corresponding author. Email: [e-mail] (K.R.S.)

Lead Contact: Kelly R. Stevens, [e-mail]

Human engineered tissues hold great promise for therapeutic tissue regeneration and repair. Yet, development of these technologies often stalls at the stage of in vivo studies due to the complexity of engineered tissue formulations, which are often composed of diverse cell populations and material elements, along with the tedious nature of in vivo experiments. We introduce a ‘plug and play’ platform called Parallelized Host Apposition for Screening Tissues in vivo (PHAST). PHAST enables parallelized in vivo testing of 43 three-dimensional microtissues in a single 3D printed device. Using PHAST, we screen microtissue formations with varying cellular and material components and identify formulations that support vascular graft-host inosculation and engineered liver tissue function in vivo. Our studies reveal that the cellular population(s) that should be included in engineered tissues for optimal in vivo performance is material-dependent. PHAST could thus accelerate development of human tissue therapies for clinical regeneration and repair.